The Big Misunderstanding: What Competition Policy Gets Wrong About Market Concentration
Executive Summary
Canada has a competition problem — but it isn’t what you think.
The challenge isn’t that too many large companies dominate their markets. It is that Canadian competition policy is moving toward treating market concentration as evidence of harm, even when concentration may be the result of firms competing successfully.
That distinction matters because scale can create real economic benefits. Large firms can spread enormous fixed costs across millions of customers, finance research that takes decades to pay off, carry spare capacity during a crisis, and build networks that become more valuable as they grow.
In many industries, the most productive firms win market share while less productive firms lose it. The result is a more concentrated market — but also a more productive one.
This matters for Canada because Parliament has recently moved competition law in a more structural direction. Since 2022, amendments to the Competition Act have strengthened the role of market concentration in merger review, while Bill C-56 repealed the long-standing efficiencies defence. Bill C-59 went further, removing the previous statutory protection against finding a merger anti-competitive based on market share or concentration alone.
The end result? Policymakers are more and more likely to equate “bigness” with harm without considering the benefits of market concentration or how firms achieved larger scale. This trend is especially risky in an economy already struggling with weak productivity and a shortage of firms capable of scaling globally.
For instance, in cloud computing, a handful of hyperscale providers dominate because data centres require enormous up-front investments. Spreading those costs across millions of customers lowers the cost of computing for everyone. In pharmaceuticals, new drugs can take decades and billions of dollars to develop. Large and profitable pharmaceutical companies can use today’s revenues to finance tomorrow’s breakthroughs, even when the payoff is uncertain. The same logic applies to advanced semiconductors, where building a leading-edge fabrication plant can cost $10 billion or more.
It’s important to note that concentration is not automatically a virtue. None of this gives large companies a licence to misbehave. Dominant firms can exclude competitors. Employers can collude to hold down wages. Companies can use contracts or other tactics to shut rivals out. Those are genuine competition problems that should be investigated and punished because of the harm they cause — not because the offending company happens to be large.
The better approach is to treat concentration as a starting point for investigation, not a presumption of guilt. Regulators should determine whether a company gained market share by offering better products at lower cost — or by blocking rivals and exploiting customers.
And when regulators weigh the potential harm of concentration, they should also consider the benefits just as seriously. Lower costs, greater resilience, and future innovation can result in cheaper services, better medicines, stronger supply chains, and more productive Canadian businesses.
The goal should not be fewer large companies. It is to improve competition. And the first step is to recognize that in business, sometimes bigger is better.